login
Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

First patients treated with Chemosat in Germany


Tuesday, 28 Feb 2012 11:12
Chemosaturation
Chemosaturation

Delcath Systems announced on 27 February that the first patients in Germany have been treated with the Delcath Hepatic Chemosat Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the company announced with the hospital in December 2011.


Two patients were treated for inoperable, liver-dominant metastases, one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications.


Thomas J Vogl, director of the Institute for Diagnostic and Interventional Radiology at JW Goethe, said, “We believe this technology has significant potential to help control cancers in the liver. We are pleased to be the first cancer centre to begin offering this important treatment option to patients in Germany, and are eager to further explore its role in the treatment of multiple tumor types including breast cancer.”


“Delcath’s partnership with JW Goethe reinforces the potential of Chemosat,” said Eamonn P Hobbs, president and CEO, Delcath. “We recently treated our first patients in Milan and are eager to continue our expansion across Europe. Opening another Chemosat treatment centre and treating patients in the continent’s largest market is another step forward in the commercialisation of this technology.”




Add New Comment

Related Items


Most popular


Biolas introduces VariClose in Europe
Thursday, 16 Jul 2015
After the European launch in April 2015, Biolas has introduced the VariClose Vein Sealing Systems in the European market for the treatment of varicose veins. Biolas introduces VariClose in Europe

Cyanoacrylate embolisation agent non-inferior to radiofrequency ablation for incompetent great saphenous veins treatment
Friday, 03 Jul 2015
Twelve-month results from the VeClose trial have demonstrated cyanoacrylate adhesive (CAE) is non-inferior to radiofrequency ablation (RFA) for the treatment of incompetent great saphenous veins. Cyanoacrylate embolisation agent non-inferior to radiofrequency ablation for incompetent great saphenous veins treatment

Companies announce new round of renal denervation randomised trials
Monday, 08 Jun 2015
Medtronic has announced the initiation of the SPYRAL HTN clinical trial programme studying renal denervation in uncontrolled hypertension, and Boston Scientific has announced the initiation of the RED... Companies announce new round of renal denervation randomised trials

Features


Choosing horses for courses: Using liquid agents to embolize endoleaks
Monday, 27 Jul 2015
Robert Morgan, vascular interventional radiologist, St Georges Hospital, London, UK, tells Interventional News why he uses liquid embolic agents, such as ethylene vinyl oxide copolymer (EVOH-based) ... Choosing horses for courses: Using liquid agents to embolize endoleaks

Aneurysm Coiling Efficiency (ACE) registry shows positive results for Ruby coil peripheral vasculature
Wednesday, 10 Jun 2015
The Aneurysm Coiling Efficiency registry offers an opportunity to study the demographics and long-term outcomes of a cohort of patients with embolization of the peripheral vasculature using Ruby ... Aneurysm Coiling Efficiency (ACE) registry shows positive results for Ruby coil peripheral vasculature

Profiles


Lindsay Machan
Thursday, 28 May 2015
“Focussing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions